Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (April 2014)
41 slides from Innate Pharma Sa Class A's investor presentation, April 2014
Slide 1: Company Presentation 2Q2014
COMPANY PRESENTATION 2Q2014 Page 1
Slide 2: Forward Looking Statement
Forward Looking Statement • This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. • This document contains forward-looking statem
Slide 3: Innate Pharma at a glance
Innate Pharma at a glance • Leading scientific edge in innate immunity pharmacology • Portfolio of first-in-class immunomodulating mAbs First-in-class immuno- • Primary focus in immuno- modulating antibodies oncology targeting innate immunity • Potential for developments in chronic Inflammation Page
Slide 4: Two first-in-class checkpoint inhibitors in clinics
Two first-in-class checkpoint inhibitors in clinics ▄ Lirilumab, anti-KIR mAb, first-in-class NK cell modulator • Development and commercialization rights licenced to Bristol-Myers Squibb in 2011 • In single-agent Phase II clinical trial and in combination with BMS checkpoint agents in two Phase I t
Slide 5: Preclinical pipeline
Preclinical pipeline ▄ IPH4102, targeting KIR3DL2, a unique tumoral antigen for rare cutaneous lymphomas • Intended for internal development • In IND-enabling studies, FHD expected early 2015 ▄ IPH33, anti-TLR3 mAb, for COPD and IBD • Ready for regulatory preclinical development • Partnering process
Slide 6: Innate Pharma's pipeline
Innate Pharma’s pipeline PROGRAM TARGET INDICATION Valid PC PI PII PIII Acute Myeloid Leukemia Lirilumab (IPH2102/BMS-986015) KIR2DL1,2,3 Solid tumors, comb. with ipilimumab licensed to Bristol-Myers Squibb Solid tumors, comb. with nivolumab IPH2201 NKG2A Cancer IPH4102 KIR3DL2 Cutaneous T-cell lymp
Slide 7: Innate Pharma positioning in immuno-oncology
Innate Pharma positioning in immuno-oncology Clinical pipeline of immunomodulating antibodies in cancer TARGET PHASE I PHASE II PHASE III MARKET Checkpoint inhibitors CTLA-4 AZN BMS PD-1 / Merck KGaA, PD-L1 AZN BMS, Merck, Roche Amplimmune /GSK, BMS KIR IPH/BMS LAG-3 BMS IMP NKG2A IPH CD137 Pfizer B
Slide 8: Investment Highlights
Investment Highlights Immunomodulating mAbs CATALYSTS • A paradigm shift in cancer treatment • Market expected >$20Bn • Start of Phase II clinical trials with IPH2201 • Lirilumab clinical Innate Pharma program read-out • One of the few listed biotech specialized in • IPH4102 first human immunomodula
Slide 9: Lirilumab
Lirilumab Page 9
Slide 10: Lirilumab: first-in-class NK cell checkpoint inhibitor
Lirilumab First-in-class NK cell checkpoint inhibitor • Fully human antibody blocking NK cell inhibitory receptor KIR2DL1/2/3 (IgG4) o Prevents interaction with HLA class 1 molecules 150 patients Class I KIR Acute Myeloid Phase II Sponsored by Innate Pharma 2012/10 ‐ MHC receptor Leukemia “EffiKIR”
Slide 11: Intergroup ALFA/Goelams EFFIKIR Phase II trial
Intergroup ALFA/Goelams EFFIKIR Phase II trial Double-blind placebo-controled randomized trial of lirilumab in AML • First randomized Phase II of lirilumab • Sponsored by Innate 1:1:1 R Lirilumab 0.1 mg/kg q 12 weeks Minimization A Intermittent full KIR occupancy N Elderly Center D CR1 1º vs 2nd AML
Slide 12: Phase I study of lirilumab in combination with nivolumab
Phase I study of lirilumab in combination with nivolumab Patients with advanced solid tumors • Dose escalation completed • Cohort expansion in various solid tumors: > Nivolumab 3mg/kg, every other weeks and lirilumab 3mg/kg, every four weeks > Patients dosed for up to two years • Participating cente
Slide 13: Phase I study of lirilumab in combination with ipilimumab
Phase I study of lirilumab in combination with ipilimumab Patients with advanced solid tumors • Regimen schedule: concurrent administration q3 weeks x 4 then q12 weeks x 4 • Dose escalation: observation period of 9 weeks after first cycle Dosage during dose escalation Total number Dose level number
Slide 14: IPH2201, anti-NKG2A
r ya IPH2201, anti-NKG2A innate pharma Page 14
Slide 15: Mechanism of action of anti-NKG2A
Mechanism of action of anti-NKG2A • CD94/NKG2A is a major checkpoint receptor on infiltrating NK cells and some CD8+ T cells • Anti-NKG2A mAb enhances immune attack on tumor cells • Blocks inhibitory signaling through NKG2A Infiltrating NK and Stressed cell CD8+ T cells Anti-NKG2A Direct killing NKG
Slide 16: Phase II ready
Phase II ready • Good safety profile in Phase I o Dose-escalation safety trial in rheumatoid arthritis patients • 92 pts, moderate RA, low-dose MTX • IV single dose (SD, up to 10 mg/kg) and SC SD and MD (up to 4 mg/kg) • No safety issues identified, MTD not reached, no DLT o Phase I completion expec
Slide 17: Potential in a variety of cancers
Potential in a variety of cancers • NKG2A is expressed on cytotoxic lymphocytes • Infiltrating NK cells, NKT cells, and some TILs • NKG2A’s ligand, HLA-E, is upregulated on a wide variety of tumor types • Can correlate with bad prognosis • Ex vivo, anti-NKG2A enhances NK or T cell killing of hematop
Slide 18: IPH22 Development Highlights
IPH22 Development Highlights 2014 2015 2016 2017 NN Phase I in RA H&N Phase II single agent - EU H&N Phase II combo cetuximab - USA CLL Phase II combo ibrutinib - USA Ovarian Phase II single agent - Canada & EU Ovarian Phase II combo SOC Page 18
Slide 19: IPH4102
IPH4102 Page 19
Slide 20: IPH4102: first-in-class drug candidate targeting KIR3DL2
IPH4102 First-in-class drug candidate targeting KIR3DL2 • Humanized cytotoxic IgG1 • Selectively binds human KIR3DL2 with high affinity • Antitumor activity in in vitro, in vivo and ex vivo models of Sezary syndrome • Start of Phase I expected beginning of 2015 http://www.innate-pharma.com/sites/def
Slide 21: Targeting KIR3DL2/CD158k
Targeting KIR3DL2/CD158k • Member of the family of inhibitory receptors modulating NK activity and is also expressed on a subset (5-10%) of normal NK et T cells • Detected on 100 % of circulating Sezary leukemic cells, on cutaneous Sezary lesions, irrespectively of disease grade as well as on transf
Slide 22: IPH43
innate pharma
Slide 23: IPH43: first-in-class anti-MICA mAb
IPH43 First-in-class anti-MICA mAb • MICA is a ligand for the activating receptor NKG2D expressed on NK cells and CD8+ T cells. Its expression is induced upon tumoral transformation A. B. • MICA expression is upregulated by chemotherapies HeLa C. D. Tissue Positive/Total cases % Positive A. Breast C
Slide 24: IPH43: first-in-class anti-MICA mAb
IPH43 First-in-class anti-MICA mAb • Newly generated anti-MICA mAb display high affinities, are pan-alleles and can mediate direct cytotoxic effect through ADCC and/or CDC (not shown) and demonstrate in vivo efficacy ADCC Curative setting (SC model) KHYG-1-hCD16 vs. C1R-MICA*08 Page 24
Slide 25: Key corporate and financial facts
Key corporate and financial facts Page 25
Slide 26: Key figures
Key figures Year ended December In thousands of euros 2013 2012 Revenue from collaboration and licensing agreements 12,469 10,377 Government financing for research expenditures 4,182 3,905 Revenue and other income 16,652 14,282 Research and development expenses (15,131) (13,417) General and administ
Slide 27: Share information and shareholders
Share information and shareholders • Listed on Euronext, IPO in November 2006 Shareholders • Euronext Paris: FR0010331421 – IPH • Indices: Next Biotech / Cac Small / CAC Pharma 11,1% & Bio 10,4% • €128m raised since inception 8,8% 55,3% • Stock liquidiy (in 2013) 5,9% • 46.7m outstanding shares (48.
Slide 28: Management team
Management team Hervé Brailly Marcel Rozencweig PhD, CEO Co-founder MD, Chief Medical Officer >30 years of experience in clinical Immunotech SA, Beckman-Coulter drug development Bristol-Myers Squibb Nicolai Wagtmann Jérôme Tiollier PhD, PhD, Chief Scientific Officer Chief Development Officer Novo No
Slide 29: 1H 2014 investors conference
1H 2014 investors conference • Oddo Midcap Forum – Lyon, January 9 and 10, 2014; • JP Morgan Healthcare conference - San Francisco, January 13 to 16, 2014; • Leerink Swann Global Healthcare Conference – New York, February 12 and 13, 2014; • Credit Suisse Healthcare Conference – London, March 4 and 5
Slide 30: Recent and upcoming scientific presentations
Recent and upcoming scientific presentations • American Society of Hematology (ASH, Dec 7 to 10, 2013, New Orleans, LA) o Posters on anti-KIR • “Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia” Sunday, December 8, 2013, 6:30 PM - 8:30 PM •
Slide 31: Bibliography
Bibliography Lirilumab, anti-KIR o Kohrt et al., 2014. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood o Vey et al., 2012. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in CR. Blood o
Slide 32: Bibliography
Bibliography IPH2201, anti-NKG2A o Levy et al., 2008. HLA-E protein is overexpressed in primary human colorectal cancer. International journal of oncology o Iwaszko et al., 2011. Clinical significance of the HLA-E and CD94/NKG2 interaction. Archivum immunologiae et therapiae experimentalis o Gunturi
Slide 33: Appendix
Appendix innate pharma age 3
Slide 34: Therapeutic potential of NK cells in Acute Myeloid Leukemia
Therapeutic potential of NK cells in Acute Myeloid Leukemia MHC KIR Class I receptor • NK cell activation shown to bring clear clinical benefit in bone marrow allografts in Acute NK Cell Myeloid Leukemia patients Stressed Cell + Activating Activating > KIR-ligand incompatibility ligand receptor KIR-
Slide 35: Phase I in AML with IPH2101
Phase I in AML with IPH2101 Hybridoma anti-KIR mAb • Elderly AML patients in complete remission after induction and consolidation treatment - maintenance setting • Phase I dose-escalation including 23 patients in first CR, and extension including 12 patients • Doses ranged from 0.0003 to 3 mg/kg – F
Slide 36: EffiKIR positioning in Acute Myeloid Leukemia
EffiKIR positioning in Acute Myeloid Leukemia Strong medical need for elderly patients • 5-year survival rate in elderly Treatment paradigm patients with AML is 5 to 15% Patients <60y (<50%) Patients >60y (>50%) ~ 50% ~ 50% • No current standard of care for elderly patients in post-induction Inducti
Slide 37: IPH33, proprietary preclinical asset
IPH33, proprietary preclinical asset A blocking mAb targeting TLR3 • Blocking TLR3 aims at preventing inflammatory cytokine production, upstream of current treatments for inflammation o Major inducer of type I IFN and inflammatory cytokines (IL-6, TNF) o Overexpressed on inflammatory epithelial cell
Slide 38: IPH33: mouse models of COPD and colitis
IPH33, proprietary preclinical asset A blocking mAb targeting TLR3 Mouse model of LPS+Elastase induced COPD Infiltrat de Neutrophiles Neutrophils infiltrationdans les Poumons in lungs Lung tissue Destruction destruction Tissulaire dans les Poumons 8 10 0 5 1.010 2 cell number in BAL Destruction I
Slide 39: Proprietary ADC technology
Proprietary ADC technology Site-specific conjugation technology for homogenous conjugates • New site-specific conjugation technology using bacterial transglutaminase (BTG) enzyme on an minimally modified antibody scaffold (single point mutation) • ADCs with DAR of exactly 2.0 or 4.0 Page 39
Slide 40: Proprietary ADC technology
Proprietary ADC technology Site-specific conjugation technology for homogenous conjugates • Stability ex vivo in human and cynomolgus plasma over one week • Stability and favorable pharmacokinetics in rat over 2 weeks • Efficacy validated in preclinical models • May be used for a broad spectrum of t
Slide 41: Investor relations
Investor relations Laure-Hélène Mercier Director, Investor relations investors@innate-pharma.com Tel: +33 (0)4 30 30 30 87 Fax: +33 (0)4 30 30 30 30 Page 41